MedPath

THE HIV NETHERLANDS AUSTRALIA THAILAND RESEARCH COLLABORATION

🇹🇭Thailand
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

60

Active:2
Completed:51

Trial Phases

5 Phases

Phase 1:6
Phase 2:18
Phase 3:3
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (41 trials with phase data)• Click on a phase to view related trials

Phase 2
18 (43.9%)
Not Applicable
8 (19.5%)
Phase 1
6 (14.6%)
Phase 4
6 (14.6%)
Phase 3
3 (7.3%)

Thailand HDV Cohort

Recruiting
Conditions
HDV
First Posted Date
2022-04-28
Last Posted Date
2024-10-02
Lead Sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Target Recruit Count
3152
Registration Number
NCT05350865
Locations
🇹🇭

HIV-NAT, Thai Red Cross - AIDS Research Centre, Bangkok, Thailand

🇹🇭

King memorial Chulalongkorn hospital, Bangkok, Thailand

🇹🇭

Siriraj Hospital, Mahidol University, Bangkok, Thailand

and more 1 locations

Microneedles for Diagnosis of LTBI

Not Applicable
Terminated
Conditions
Latent Tuberculosis
First Posted Date
2020-09-17
Last Posted Date
2023-03-01
Lead Sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Target Recruit Count
4
Registration Number
NCT04552015
Locations
🇹🇭

Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Self-Assessment Tuberculin Skin Test

Completed
Conditions
Tuberculin Skin Test
First Posted Date
2019-02-11
Last Posted Date
2020-07-16
Lead Sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Target Recruit Count
215
Registration Number
NCT03835832
Locations
🇹🇭

HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

🇹🇭

Taksin Hospital, Bangkok, Thailand

Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

Phase 3
Active, not recruiting
Conditions
HIV-infected Participants With Latent TB Infection in High TB Burden Country
Interventions
Drug: Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Drug: Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
First Posted Date
2018-12-24
Last Posted Date
2025-03-17
Lead Sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Target Recruit Count
2500
Registration Number
NCT03785106
Locations
🇹🇭

Klang Hospital, Bangkok, Thailand

🇹🇭

Bhumibol Adulyadej Hospital, Bangkok, Thailand

🇹🇭

HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

and more 13 locations

Efficacy, Safety and Pharmacokinetics of DTG with RIF

Phase 2
Recruiting
Conditions
HIV/TB Coinfection
Interventions
Drug: DTG 50 mg OD with food
Drug: DTG 50 mg BID
First Posted Date
2018-11-06
Last Posted Date
2024-10-02
Lead Sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Target Recruit Count
200
Registration Number
NCT03731559
Locations
🇹🇭

Infectious Disease Chiangrai Prachanukroh Hospital, Chiang Rai, Chiangrai, Thailand

🇹🇭

Klang Hospital, Bangkok, Thailand

🇹🇭

Bhumibol Adulyadej Hospital, Bangkok, Thailand

and more 7 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 12
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.